title: Effects of mepartricin (S-160) on spontaneous canine benign prostatic hyperplasia.
abstract: OBJECTIVE
  The effects of mepartricin (S-160) on spontaneous canine benign prostatic hyperplasia (BPH) were investigated by histological, histochemical and biochemical analysis.
  
  
  METHODS
  Aged beagle dogs (5-9 years old) with spontaneously developed BPH were treated orally with a placebo or S-160 (5, 10 or 20 mg/kg/day) for 8 weeks. The methodology included measurement of prostatic volume by transrectal ultrasonography, qualitative evaluation of prostatic morphology, determination of plasma and intraprostatic estradiol level by radioimmunoassay and immunohistochemical detection of estrogen receptors and androgen receptors in the prostate.
  
  
  RESULTS
  S-160 significantly reduced the prostatic volume and regressed histologically the hyperplastic grade of prostate, and also fairly decreased the plasma and intraprostatic estradiol concentration and the estrogen and androgen receptors in the prostate.
  
  
  CONCLUSIONS
  These results suggest that the reduction of estradiol and estrogen receptors in the prostate may play a crucial role in the regression of BPH by S-160.
authors.affiliation: Tokyo Research Laboratories, Kowa Co. Ltd, Higashi-murayama, Tokyo, Japan. y-yosink@kowa.co.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshinaka
authors.forename: H
authors.initials: H
authors.lastname: Kobayasi
authors.forename: J
authors.initials: J
authors.lastname: Kirihara
authors.forename: F
authors.initials: F
authors.lastname: Sato
authors.forename: S
authors.initials: S
authors.lastname: Shakutou
authors.forename: H
authors.initials: H
authors.lastname: Yamanaka
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000737:chemistry; D001707:Biopsy, Needle; D004195:Disease Models, Animal; D004285:Dogs; D004958:Estradiol / Q000032:analysis; D007150:Immunohistochemistry; D008297:Male; D008613:Mepartricin / Q000008:administration & dosage* / Q000737:chemistry; D011467:Prostate / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D011944:Receptors, Androgen / Q000032:analysis; D012016:Reference Values; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000900:Anti-Bacterial Agents; D011944:Receptors, Androgen; D008613:Mepartricin; D004958:Estradiol